Katrine Bosley is an entrepreneur who has been part of the biotech industry for over 30 years.
She is Chairman of the Board of Arrakis Therapeutics, founding CEO of DaCapo Brainscience, and a Board member of Genocea Biosciences, of the Mass Eye and Ear Institute, and of the Institute of Contemporary Art in Boston.
Katrine was CEO of Editas Medicine, the first company established to develop CRISPR-based gene editing therapeutics, where she built the company from its early days through its IPO and advancement of its first program to clinical development – the first ever in vivo CRISPR-based medicine. Prior to Editas, Katrine was CEO of Avila Therapeutics through its acquisition by Celgene. Before that she was Entrepreneur-in-Residence at The Broad Institute, was VP Business Development at Adnexus Therapeutics/Bristol Myers-Squibb, held various roles at Biogen, Highland Capital Partners, and Alkermes.
Katrine’s prior Board roles include serving as Chair of the Emerging Companies Section of the Board of the Biotechnology Innovation Organization (BIO), and as a member of the boards of Galapagos NV and Scholar Rock, Inc. She is a graduate of Cornell University.
Katrine has been recognized as one of the 100 Most Creative People in Business by Fast Company, as CEO of the Year by Xconomy, as one of 30 Global Game Changers by Forbes, as Entrepreneur of the Year by the New England Venture Capital Association, and as one of the Top Ten Women in Biotech by FierceBiotech.
